louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03622853: What Factors Area Associated With Prognosis After Steroid Hydrodilatation for Adhesive Capsulitis
Official title: What Factors Area Associated With Prognosis After Steroid Hydrodilatation for Adhesive Capsulitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Adhesive Capsulitis
Keywords: adhesive capsulitis
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2018-08-09
Enrollment: 100
Sex: ALL
Minimum age (years): 35
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: To investigate the factors associated with improvement after intraarticular steroid injection for patients with Frozen shoulder
Primary purpose: TREATMENT

Brief summary: To investigate the factors associated with improvement after intraarticular steroid injection for patients with Frozen shoulder

Detailed description: Objective: To investigate the factors associated with improvement after intraarticular steroid injection for patients with Frozen shoulder

Design: Prospective study.

Participants: Patients with Frozen shoulder were recorded the demographic data, associated disease, ultrasound findings at baselines.

Intervention: One shot intraarticular steroid hydrodilatation

Main Outcome Measures: Visual analog scale (VAS) of the shoulder pain, Constant score, SPADI score, and angles of active and passive shoulder range of motion (flexion, abduction, external rotation, and internal rotation) at pre-treatment, post-treatment at week 8

Eligibility criteria: Inclusion Criteria:

* Diagnosis of frozen shoulder by physical examination and ultrasonography

Exclusion Criteria:

1. other conditions involving the shoulder ( rheumatoid arthritis, Hill-Sachs lesions,osteoporosis, or malignancies in the shoulder region);
2. neurologic deficits affecting shoulder function in normal daily activities;
3. shoulder pain caused by cervical radiculopathy
4. a history of drug allergy to xylocaine
5. pregnancy or lactation;
6. received injection into the affected shoulder during the preceding 3 months

Primary outcomes:
measure: The change of constant shoulder score between week 0 and week 8
timeFrame: 0 and 8 wks
Secondary outcomes:
measure: pain intensity
timeFrame: 0 and 8 wks
measure: Shoulder Pain And disability index
timeFrame: 0 and 8 wks
measure: glenohumeral joint range of motion
timeFrame: 0 and 8 wks
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
Study officials:
References:
Clinical trial NCT06945653: DEI Education in Anesthesiology
Official title: An Assessment of Diversity, Equity and Inclusion Education in Anesthesiology: A Survey of the American Society of Anesthesiologists (ASA) Members
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Diversity
Lead sponsor: Hospital for Special Surgery, New York
Sponsor class: OTHER
First posted: 2025-04-25
Enrollment: 3000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Members of the American Society of Anesthesiologists, including learners at all levels - medical students, residents and fellows - as well as attending anesthesiologists, CRNAs, research staff, etc.

Brief summary: To date, there has not been an assessment of ASA members to determine satisfaction with DEI and cultural humility/structural competency education within institutions and programs. We developed a 24-question survey that will be distributed via email to current members of the American Society of Anesthesiologists. Members include learners at all levels - medical students, residents and fellows - as well as attending anesthesiologists, CRNAs, research staff etc. The survey questions are aimed to assess the current state of diversity training in anesthesiology education. This survey serves as a needs assessment and will help gather information on the current state of DEI education within the specialty. The results of the survey will serve as an impetus for improvement in this domain by developing novel educational modules and workshops on these topics, at the institutional level and nationwide.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologist Member

Exclusion Criteria:

* Not a member of the American Society of Anesthesiologists

Primary outcomes:
measure: Demographic Characteristics
timeFrame: Through study completion, about 2 months
measure: Current Knowledge
timeFrame: Through study completion, about 2 months
measure: Training Methods
timeFrame: Through study completion, about 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01356953: Exercise Intensity and Type 2 Diabetics
Official title: Effects of Exercise Intensity on 24-h Ambulatory Blood Pressure in Type 2 Diabetics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes
Keywords: Aerobic Exercise
Blood Pressure
Lead sponsor: Catholic University of Brasília
Sponsor class: OTHER
Collaborators: name: Conselho Nacional de Desenvolvimento Científico e Tecnológico
First posted: 2011-05-20
Enrollment: 10
Sex: ALL
Minimum age (years): 45
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a single session of aerobic exercise effectively controls the blood pressure (BP) of individuals with type 2 diabetes mellitus (T2DM) over the 24h of post-exercise period, and the effects of intensity of aerobic exercise on these BP responses.


Eligibility criteria: Inclusion Criteria:

* sedentary
* a diagnosis of T2DM for at least one year
* glycemic control through nutrition and/or medication

Exclusion Criteria:

* be not under use of exogenous insulin and do not present chronic complications such as diabetic foot
* nephropathy
* retinopathy
* neuropathies and cardiovascular diseases

Primary outcomes:
measure: Blood Pressure - Ambulatory blood pressure monitoring (ABPM)
timeFrame: Participants will be followed for the duration of experimental tests, an expected average of 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Taguatinga
country: Brazil
facility: Catholic University of Brasilia
Study officials:
References:
Clinical trial NCT06686953: The Effect of Environmental Pollution on Colorectal Cancer
Official title: Clinical Study of the Effect of Environmental Pollution on the Prognosis of Colorectal Cancer.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Carcinoma
Keywords: colorectal cancer
environment
airpollution
greenness
Lead sponsor: First Affiliated Hospital of Chongqing Medical University
Sponsor class: OTHER
First posted: 2024-11-13
Enrollment: 6300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients diagnosed as colorectal cancer

Brief summary: Colorectal cancer (CRC) is one of the most common malignancies worldwide, and its main risk factors include age, genetic factors, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), unhealthy diets (e.g., high-fat, low-fibre diets), obesity, physical inactivity, smoking, and excessive alcohol consumption. The relationship between environmental pollution and colorectal cancer has received increasing attention in recent years. Studies have shown that long-term exposure to fine particulate matter in the air, such as passive smoking, soot and oil smoke exposure, incense burning exposure, occupational exposure and outdoor work, PM2.5, PM10 and NO2 may increase the risk of colorectal cancer. These particulate matter can enter the lungs through breathing and trigger a chronic inflammatory response in the systemic system, thus increasing the risk of cancer development. This study intends to determine the extent of air pollution's impact on colorectal cancer prognosis by analysing survival data of colorectal cancer patients in regions with different pollution levels. As well as to investigate the association between air pollution levels and postoperative recurrence in colorectal cancer patients, looking for possible mechanisms.


Eligibility criteria: Inclusion Criteria:

* age ≥18 years;
* patients diagnosed with colorectal cancer by pathological biopsy before surgery;
* patients did not undergo chemotherapy, radiotherapy, targeted and immunotherapy, etc. before enrolment;
* willing to participate in this study and sign an informed consent form;
* complete clinical data.

Exclusion Criteria:

* patients with primary malignant tumours other than colorectal cancer;
* patients with systemic diseases, such as severe cardiopulmonary insufficiency, that affect the choice of treatment options;
* patients who are not suitable for enrolment as assessed by the investigator;
* incomplete clinical data.

Primary outcomes:
measure: colorectal cancer
timeFrame: From 18 years old until the developing colorectal cancer, through study completion, an average of 5 year.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02877953: Transitional Care Interventions for Patients With Cirrhosis Post-TIPS
Official title: Transitional Care Interventions Post-TIPS
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fibrosis
Lead sponsor: Shihezi University
Sponsor class: OTHER
First posted: 2016-08-24
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators conducted a randomized controlled trial to describe if multidisciplinary and patient-centered transitional care interventions for patients with cirrhosis post-TIPS can improve compliance behavior and reduce complications post-TIPS after discharge.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of diagnosis of cirrhosis;
* Child-Pugh Score \<10;
* Informed Consent.

Exclusion Criteria:

* Age \<18 years;
* Right ventricular failure;
* Severe systemic infection;
* Hepatocellular carcinoma (HCC);
* Terminal disease; and
* Failure to provide written consent to participate in the study.

Primary outcomes:
measure: The compliance behavior associated with complications post-TIPS
timeFrame: 1 and 3 months after discharge
Secondary outcomes:
measure: incidence of adverse events (shunt dysfunction and hepatic encephalopathy)
timeFrame: 1 and 3 months after discharge
measure: Child-Pugh scores
timeFrame: Baseline, 1 and 3 months after discharge
measure: Blood ammonia levels
timeFrame: Baseline, 1 and 3 months after discharge
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05333653: Supportive Care During Childbirth and Well-being
Official title: The Effect of Continous Supportive Care at Childbirth on Maternal Psychological Well-being: A Single-blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Psychological Well-being
Childbirth
Care Pattern, Maternal
Keywords: Intrapartum supportive care
birth trauma
fear of childbirth
maternal attachment
perinatal well-being
Lead sponsor: Mersin University
Sponsor class: OTHER
First posted: 2022-04-19
Enrollment: 59
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to evaluate the effects of continuous supportive care (ICSC) at birth on some parameters of maternal psychological well-being.

Detailed description: This is a single-blind randomized controlled trial. Data were collected from 80 women who gave birth in the obstetrics clinic of a state hospital in the south of Turkey between December 2020 and June 2021. Participants who met the inclusion criteria were informed about the purpose of the study and the procedures to be performed, informed consent was obtained from those who agreed to participate, and women were assigned to the groups in line with a computer-based randomization program with an allocation ratio of 1:1. Block randomization could not be performed because of the different and long delivery processes. Data were collected in both groups at birth (latent phase, active phase, and transitional phase), within 24 hours of birth, and 6th-8th postpartum days after hospital admission and at least one hour of care. collected by the first author. The CONSORT directive was followed in the planning, implementation and writing of the research.

Eligibility criteria: Inclusion Criteria:

* The ages of 18-40 women,
* At least primary school graduate,
* Mother tongue Turkish,
* Single fetus,
* Term,
* Spontaneous birth,
* Cervical dilatation between 0-6 cm (latent phase) and without a condition that could prevent vaginal delivery.
* Primiparous and multiparous women
* Not have any disease or complication and agreed to participate in the study were included.

Exclusion Criteria:

* Women who developed a complication with the fetus or themselves during delivery,
* Underwent emergency cesarean section,
* Not be reached during follow-ups by telephone,
* Wanted to withdraw from the study

Primary outcomes:
measure: Fear of Childbirth (DFS)
timeFrame: through delivery, an average of 24th hours
measure: Perceived control and support in birth (SCIB)
timeFrame: Postpartum 24th hours
measure: Birth Trauma (City BITS)
timeFrame: Postpartum 8 th week
measure: Maternal Attachment (MAI)
timeFrame: Postpartum 8 th week
Secondary outcomes:
Other outcomes:
Locations:
city: Mersin
country: Turkey
facility: Gozde Gokce Isbir
Study officials:
affiliation: Mersin University
name: Gozde Gokce Isbir
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00547053: Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis
Official title: A Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cystic Fibrosis
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
Collaborators: name: Cystic Fibrosis Foundation
First posted: 2007-10-19
Enrollment: 25
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to determine if multiple doses of two inhaled drugs will help Cystic Fibrosis patients whose lungs are infected with a bacteria called Burkholderia dolosa. The names of these drugs are tobramycin solution for inhalation and amiloride solution for inhalation. Currently, treating patients with Burkholderia dolosa infections is challenging because the bacteria is resistant to antibiotics. Therefore, researchers are looking for drugs which, when taken with an antibiotic, will help the antibiotic to work more effectively.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Cystic Fibrosis
* Two positive cultures for Burkholderia dolosa lung infection

Exclusion Criteria:

* Positive pregnancy test or currently breast feeding (if applicable)
* Known sensitivity to Amiloride

Primary outcomes:
measure: Eradication of Burkholderia dolosa.
timeFrame: 1 month, 3 months, and 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Children's Hospital
state: Massachusetts
Study officials:
affiliation: Boston Children's Hospital
name: Dawn Ericson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02534753: A Pharmacokinetics Study of Intravenous Ascorbic Acid
Official title: A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pharmacokinetics
Lead sponsor: McGuff Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2015-08-28
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.

Detailed description: The objectives of this study are:

1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV).
2. To evaluate the safety and tolerability of AA administered intravenously.

Eligibility criteria: Inclusion Criteria:

* Is between the ages of 18 and 45 years, inclusive.
* Has a body mass index (BMI) between 18 and 32 kg/m2.
* Of sound health and has the ability to understand the requirements of the study and is willing to comply with all study requirements and procedures.

Exclusion Criteria:

* Participates in activities that would not allow accurate evaluation of the pharmacokinetics of Ascorbic Acid
* Medical or physical conditions that would not allow safe participation and/or accurate evaluation of the pharmacokinetics of Ascorbic Acid
* Has participated in an investigational drug study within the 30 days prior to CRU admission.

Primary outcomes:
measure: Concentration of Ascorbic Acid (µM) in plasma
timeFrame: 1 day
Secondary outcomes:
measure: Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) grouped by body system
timeFrame: 1 day
measure: Changes from Baseline in clinical laboratory and vital signs to discharge
timeFrame: 1 day
measure: Changes from pre-dose physical exam findings to discharge
timeFrame: 1 day
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
Study officials:
affiliation: McGuff Pharmaceuticals, Inc.
name: Damon P Jones, BS/MBA
role: STUDY_DIRECTOR
References:
Clinical trial NCT06189053: A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
Official title: Long-term Outcomes of Myocarditis Following Administration of SPIKEVAX (COVID-19 Vaccine mRNA)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Myocarditis
Keywords: mRNA-1273
mRNA-1273 vaccine
SARS-CoV-2
SARS-CoV-2 Vaccine
Coronavirus
Virus Diseases
Messenger RNA
COVID-19
COVID-19 Vaccine
Moderna
Lead sponsor: ModernaTX, Inc.
Sponsor class: INDUSTRY
First posted: 2024-01-03
Enrollment: 1500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The source population for this study will include participants with a diagnosis of myocarditis or a relevant combination of laboratory and clinical findings meeting the Centers for Disease Control and Prevention (CDC) case definition for probable or confirmed myocarditis occurring during the study window for case ascertainment.

Brief summary: The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.

Detailed description: This is an observational cohort study that combines data collected directly from healthcare providers (HCP) with existing retrospective real-world data as captured in clinical electronic health record (EHR) and administrative claims data. Vaccine exposure and case identification information will be obtained retrospectively from existing real-world data to identify cases of post-vaccine myocarditis (PVM) and ultimately vaccine-associated myocarditis (VAM) for potential study inclusion. Eligible participants will be identified and followed for up to 5 years until the end of the study period or loss to follow-up or death.

Eligibility criteria: Inclusion Criteria:

* Participants with a diagnosis of myocarditis between December 18, 2020, and October 31, 2026, will be identified or who have a relevant combination of laboratory and clinical findings meeting the CDC case definition for probable or confirmed myocarditis will be included in the study.
* Participants will be required to have at least 30 days of medical history to assess SPIKEVAX exposure.

Primary outcomes:
measure: Number of Participants with Major Adverse Clinical Outcomes
timeFrame: Up to 5 years
measure: Number of Participants with Persistent Cardiac Abnormality
timeFrame: Up to 5 years
measure: Functional Assessment: Number of Participants Reporting Symptoms of Chest Pain, Dyspnea, Palpitations, and Syncope
timeFrame: Up to 5 years
measure: Functional Assessment: Number of Participants Returning to Normal Activities
timeFrame: Up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Veradigm
state: Illinois
Study officials:
References: